Preliminary trial of rebamipide for prevention of low-dose aspirin-induced gastric injury in healthy subjects: A randomized, double-blind, placebo-controlled, cross-over study

Journal of Clinical Biochemistry and Nutrition

Volumn 45, Issue 2, 2009, Pages 248-253

  Ono, Shouko ^a   Kato, Mototsugu ^a   Imai, Aki ^b   Yoshida, Takeshi ^b   Hirota, Jyojyo ^b   Hata, Tamotsu ^b   Takagi, Kikuko ^b   Kamada, Go ^b   Ono, Yuji ^b   Nakagawa, Manabu ^a   Nakagawa, Souichi ^a   Shimizu, Yuichi ^a   Takeda, Hiroshi ^b   Asaka, Masahiro ^b  

^a HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Healthy subject; Low dose aspirin; Prevention; Rebamipide

Indexed keywords

ACETYLSALICYLIC ACID; PLACEBO; REBAMIPIDE;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ERYTHEMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN EXPERIMENT; LOW DRUG DOSE; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; STOMACH ANTRUM; STOMACH EROSION; STOMACH HEMORRHAGE; STOMACH INJURY; STOMACH ULCER;

EID: 70350334550     PISSN: 09120009     EISSN: None     Source Type: Journal    
DOI: 10.3164/jcbn.09-24     Document Type: Article

References (34)

1. Marshall, B.J.: Helicobacter pylori. Am. J. Gastroenterol., 89, S116-S128, 1994.
2. Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M.B., Hawkey, C.J., Hochberg, M.C., Kvien, T.K., and Schnitzer, T.J.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl. J. Med., 343, 1520-1528, 2000.
3. Silverstein, F.E., Faich, G., Goldstein, J.L., Simon, L.S., Pincus, T., Whelton, A., Makuch, R., Eisen, G., Agrawal, N.M., Stenson, W.F., Burr, A.M., Zhao, W.W., Kent, J.D., Lefkowith, J.B., Verburg, K.M., and Geis, G.S.: Gastrointestinal toxicity with celecoxib vs. nonsteroidal antiinflammatory drugs for osteoarthritis and rheumatoid arthritis; the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA, 284, 1247-1255, 2000.
4. Suzuki, H., Hibi, T., and Marshall, B.J.: Helicobacter pylori: present status and future prospects in Japan. J. Gastroenterol., 42, 1-15, 2007. (Pubitemid 46357245)
5. Nishikawa, K., Sugiyama, T., Kato, M., Ishizuka, J., Komatsu, Y., Kagaya, H., Katagiri, M., Nishikawa, S., Hokari, K., Takeda, H., and Asaka, M.: Non-Helicobacter pylori and non-NSAID peptic ulcer disease in the Japanese population. Eur. J. Gastrol. and Hepatol., 12, 635-640, 2000.
6. Antithrombotic Trialists' Collaboration: Collaborative meta-analysis of randomized trials of ant platelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ, 324, 71-86, 2002. (Pubitemid 34073138)
7. Lauer, M.S.: Aspirin for primary prevention of coronary events. N. Engl. J. Med., 346, 1468-1474, 2002.
8. The Dutch TIA Trial Study Group: A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N. Engl. J. Med., 325, 1261-1266, 1991.
9. Cryer, B. and Feldman, M.: Effect of very low dose daily, long-term aspirin therapy on gastric, duodenal, and, rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology, 117, 17-25, 1999. (Pubitemid 29297615)
10. Howkey, C. and Lanes, A.: Double and certainly about NSAIDs in the year 2000; a multidisciplinary expert statement. On behalf of the Sardinia NSAID meeting participants. Am. J. Med., 110, S79-S100, 2001.
11. Dammann, H.G., Burkhardt, F., and Wolf, N.: Enteric coating of aspirin significantly decreases gastroduodenal mucosal legions. Aliment. Pharmacol. Ther., 13, 1109-1114, 1999.
12. Hawthorne, A.B., Mahida, Y.R., Cole, A.T., and Howkey, C.J.: Aspirin-induced gastric mucosal damage: prevention by enteric-coating and relation to prostaglandin synthesis. Br. J. Clin. Pharmacol., 32, 77-83, 1991.
13. Cole, A.T., Hudson, N., Hawkey, C.J., and Hepinstall, S.: Protection of human gastric mucosa against aspirin-enteric coating or dose reduction?. Aliment. Pharmacol. Ther., 13, 187-193, 1999.
14. Petroski, D.: A comparison of aspirin granules with plain and buffered aspirin: a report of two studies. Am. J. Gastroenterol., 81, 26-28, 1986.
15. Laine, L., Maller, E.S., Yu, C., Quan, H., and Simon, T.: Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. Gastroenterology, 127, 395-402, 2004. (Pubitemid 39091887)
16. Murakami, K., Okajima, K., Uchiba, M., Harada, N., Johno, M., Okabe, H., and Takatsuki, K.: Rebamipide attenuates indomethacin-induced gastric mucosal legion formation by inhibiting activation of leukocytes in rats. Dig. Dis. Sci., 42, 319-325, 1997.
17. Kleine, A., Kluge, S., and Peskar, B.M.: Stimulation of prostaglandin biosynthesis mediates gastroprotective effect of rebamipide in rats. Dig. Dis. Sci., 38, 1441-1449, 1993.
18. Suzuki, M., Miura, S., Mori, M., Kai, A., Suzuki, H., Fukumura, D., Suematsu, M., and Tsuchiya, M.: Rebamipide, a novel antiulcer agent, attenuates Helicobacter pylori induced gastric mucosal cell injury associated with neutrophil derived oxidants. Gut, 35, 1375-1378, 1994. (Pubitemid 24310895)
19. Oka, S., Ogino, K., Hobara, T., Yoshimura, S., Okazaki, Y., Takemoto, T., and Iida, Y.: Effects of various mucosal protective drugs on diethyldithiocarbamate-induced antral ulcer in rats. Eur. J. Pharmacol., 197, 99-102, 1991.
20. Dammann, H.G.: Effect of rebamipide on aspirin-induced gastric damage: a case-control study. Eur. J. Gastrol. Hepatol., 6, 911-915, 1994.
21. Awtry, E.H. and Loscalzo, J.: Aspirin. Circulation, 101, 1206-1218, 2000.
22. Benedek, I.H., Joshi, A.S., Pieniaszek, H.J., King, S.Y., and Kornhauser, D.M.: Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteers. J. Clin. Pharmacol., 35, 1181-1186, 1995.
23. Patrono, C., Ciabattoni, G., Pinea, E., Pugliese, F., Castrucci, G., De Salvo, A., Satta, M.A., and Peskar, B.A.: Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb. Res., 17, 317-327, 1980.
24. Rodriguez, L.A.G. and Jick, H.: Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet, 343, 769-772, 1994.
25. Lai, K.C., Lam, S.K., Chu, K.M., Wong, B.C., Hui, W.M., Hu, W.H., Lau, G.K., Wong, W.M., Yuen, M.F., Chan, A.O., Lai, C.L., and Wong, J.: Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N. Engl. J. Med., 346, 2033-2038, 2002.
26. Cook, D., Guyatt, G., Marshall, J., Leasa, D., Fuller, H., Hall, R., Peters, S., Rutledge, F., Griffith, L., McLellan, A., Wood, G., and Kirby, A.: A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. N. Engl. J. Med., 338, 791-797, 1998.
27. Naito, Y., Yoshikawa, T., Iinuma, S., Yagi, N., Matsuyama, K., Boku, Y., Fujii, T., Yoshida, N., Kondo, M., and Sasaki, E.: Rebamipide protects against indomethacin-induced gastric mucosal injury in healthy volunteers in a double-blind, placebo-controlled study. Dig. Dis. Sci., 43, S83-S89, 1998. (Pubitemid 28433955)
28. Naito, Y., Iinuma, S., Yagi, N., Boku, Y., Imamoto, E., Takagi, T., Handa, O., Kokura, S., and Yoshikawa, T.: Prevention of indometacin-induced gastoric mucosal injury in Helicobacter pylori-Negative healthy volunteers: A comparison study rebamipid vs Famotidine. J. Clin. Biochem. Nutr., 43, 34-40, 2008.
29. Wallace, J.L.: Pathogenesis of NSAID-induced gastroduodenal mucosal injury. Best Pract. Res. Clin. Gastroenterol., 15, 691-703, 2001.
30. Kim, H.K., Kim, J.I., Kim, J.K., Han, J.Y., Park, S.H., Choi, K.Y., and Chung, I.S.: Preventive effects of rebamipide on NSAID-induced gastric mucosal injury and reduction of gastric mucosal blood flow in healthy volunteers. Dig. Dis. Sci., 52, 1776-1782, 2007.
31. Asaki, S.: NSAIDs induced gastroduodenal ulcer in the aged. Nippon Rinsho, 60, 1527-1532, 2002.
32. Stiel, D., Ellard, K.T., Hills, L.J., and Brooks, P.M.: Protective effect of enprostil against aspirin-induced gastroduodenal mucosal injury in man. Comparison with cimetidine and sucralfate. Am. J. Med., 81, 54-58, 1986.
33. Martin, G., Wex, T., Treiber, G., Malfeteiner, P., and Nardone, G.: Low-dose aspirin reduces the gene expression of gastrokine-1 in the antral mucosa of healthy subjects. Aliment. Pharmacol. Ther., 28, 782-788, 2008.
34. Sørensen, H.T., Mellemkjaer, L., Blot, W.J., Nielsen, G.L., Steffensen, F.H., McLaughlin, J.K., and Olsen, J.H.: Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am. J. Gastroenterol., 95, 2218-2224, 2000.